425 related articles for article (PubMed ID: 23159849)
21. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas.
Sun X; Liu M; Wei Y; Liu F; Zhi X; Xu R; Krissansen GW
Cancer Gene Ther; 2006 Apr; 13(4):428-35. PubMed ID: 16211089
[TBL] [Abstract][Full Text] [Related]
23. STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination.
Jung JE; Kim HS; Lee CS; Shin YJ; Kim YN; Kang GH; Kim TY; Juhnn YS; Kim SJ; Park JW; Ye SK; Chung MH
Exp Mol Med; 2008 Oct; 40(5):479-85. PubMed ID: 18985005
[TBL] [Abstract][Full Text] [Related]
24. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
25. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
Corn PG; McDonald ER; Herman JG; El-Deiry WS
Nat Genet; 2003 Nov; 35(3):229-37. PubMed ID: 14556007
[TBL] [Abstract][Full Text] [Related]
26. pVHL mediates K63-linked ubiquitination of nCLU.
Xue J; Lv DD; Jiao S; Zhao W; Li X; Sun H; Yan B; Fan L; Hu RG; Fang J
PLoS One; 2012; 7(4):e35848. PubMed ID: 22532874
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1α and hierarchical quality control of pVHL via chaperone system.
Ni J; Ni A
PLoS One; 2021; 16(7):e0248019. PubMed ID: 34329303
[TBL] [Abstract][Full Text] [Related]
28. Suppression of von Hippel-Lindau Protein in Fibroblasts Protects against Bleomycin-Induced Pulmonary Fibrosis.
Zhou Q; Chen T; Zhang W; Bozkanat M; Li Y; Xiao L; van Breemen RB; Christman JW; Sznajder JI; Zhou G
Am J Respir Cell Mol Biol; 2016 May; 54(5):728-39. PubMed ID: 26488390
[TBL] [Abstract][Full Text] [Related]
29. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
30. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice.
Wang J; Ma Y; Jiang H; Zhu H; Liu L; Sun B; Pan S; Krissansen GW; Sun X
J Hepatol; 2011 Aug; 55(2):359-68. PubMed ID: 21168458
[TBL] [Abstract][Full Text] [Related]
32. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
[TBL] [Abstract][Full Text] [Related]
33. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
35. Phospholipase D2 promotes degradation of hypoxia-inducible factor-1α independent of lipase activity.
Park MH; Bae SS; Choi KY; Min do S
Exp Mol Med; 2015 Nov; 47(11):e196. PubMed ID: 26611735
[TBL] [Abstract][Full Text] [Related]
36. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
37. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
38. Nur77 upregulates HIF-alpha by inhibiting pVHL-mediated degradation.
Kim BY; Kim H; Cho EJ; Youn HD
Exp Mol Med; 2008 Feb; 40(1):71-83. PubMed ID: 18305400
[TBL] [Abstract][Full Text] [Related]
39. Low frequency of HIF-1α overexpression in germ cell tumors of the testis.
Vranic S; Hes O; Grossmann P; Gatalica Z
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):165-9. PubMed ID: 22820662
[TBL] [Abstract][Full Text] [Related]
40. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
